Lumida
/BMY
⌘K
Bristol-Myers Squibb Co

Bristol-Myers Squibb Co

BMY
$63.64USD-0.17%-0.11 today

MARKET CAP

130.0B

P/E (TTM)

17.9x

FWD P/E

DAY RANGE

$63 – $64

52W RANGE

$43
$69

AI Summary

Stalk
StalkMedium

Despite the medium-term uptrend, short-term momentum has weakened as price trades below the 9- and 20-day EMAs and pulls into the 50-day SMA. The 50-day SMA near 63.4 offers a high-quality support zone for a pullback-based entry in line with Growth at Reasonable Price principles. Execution should be deferred until the pullback is absorbed and price stabilizes around the 50-day SMA.

  • Q2 2026 revenue $7.3 B, up 14% YoY on robust growth portfolio
  • FDA accelerated approval of ZENBEXUS™ for multiple myeloma boosts pipeline
  • Analysts lower growth and revisions outlook; Milvexian study behind schedule
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$46.4B$46.2B$45.0B$48.3B$48.2B
YoY %+9.1%-0.5%-2.5%+7.3%-0.2%
P / Sales3.0x3.4x2.4x2.4x2.3x
EV / Sales4.3x4.6x3.6x3.7x3.6x
Gross Profit, Adj.$36.4B$36.0B$34.3B$34.3B$34.3B
YoY %+18.5%-1.2%-4.7%+0.1%-0.2%
Margin %78.6%78.0%76.2%71.1%71.1%
EV / Gross Profit5.5x5.9x4.8x5.3x5.0x
EBITDA, Adj.$18.1B$18.6B$17.0B$2.1B$14.0B
YoY %+1411.6%+2.8%-8.2%-87.6%+562.9%
Margin %38.9%40.2%37.9%4.4%29.1%
EV / EBITDA11.0x11.4x9.6x85.4x12.2x
EBIT$7.4B$8.3B$7.3B$-7.5B$10.0B
YoY %+180.3%+12.3%-12.1%-202.8%+233.6%
Margin %15.9%18.0%16.2%-15.5%20.8%
EV / EBIT27.0x25.5x22.5x-24.1x17.1x
Net Income$7.0B$6.3B$8.0B$-8.9B$7.1B
YoY %+177.6%-9.5%+26.8%-211.5%+178.8%
Net Margin15.1%13.7%17.8%-18.5%14.6%
EPS (GAAP)$3.12$2.95$3.86-$4.41$3.46
YoY %+178.2%-5.4%+30.8%-214.2%+178.5%